Quarterly Financial & Operational Results Release and Dividends - Research Reports on AFLAC, BlackRock, Allergan, Cabot and Cheniere Energy

NEW YORK, November 3, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding AFLAC Inc. (NYSE: AFL), BlackRock, Inc (NYSE: BLK), Allergan Inc. (NYSE: AGN), Cabot Oil & Gas Corporation (NYSE: COG) and Cheniere Energy, Inc. (NYSEMKT: LNG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7630-100free.

--
AFLAC Inc. Research Reports
On October 28, 2014, AFLAC Inc. (AFLAC) announced its Q3 2014 financial results. Total revenues stood at $5.7 billion, compared with $5.9 billion in Q3 2013, reflecting weaker yen/USD exchange rate. Operating earnings per diluted share stood at $1.51 versus $1.47 in Q3 2013. Net earnings were $706 million, or $1.56 per diluted share, compared with $702 million, or $1.50 per diluted share in Q3 2013. AFLAC's Chairman and CEO, Daniel P. Amos stated, "We are pleased with our overall financial results in the third quarter of 2014 and for the first nine months of the year. Aflac Japan, our largest earnings contributor, generated strong financial results for the quarter. During the quarter, we successfully launched our "New Cancer DAYS" product available for sale through all distribution channels in Japan." The full research reports on AFLAC are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/AFL/report.pdf

--
BlackRock, Inc Research Reports
On October 15, 2014, BlackRock, Inc. (BlackRock) announced its Q3 2014 financial results. Revenue was reported at $2.8 billion, up 15.3% YoY. Asset under management (AUM) increased 10.5% YoY to $4,524.6 billion. Net income stood at $917 million or $5.37 per diluted share, compared to $730 million or $4.21 per diluted share in Q3 2013. Laurence D. Fink, Chairman and CEO of BlackRock commented, "BlackRock's unique business model, combining active and index products on a single platform alongside Aladdin's industry-leading risk management and analytics capabilities, once again delivered strong results in the third quarter. We continue to invest in our platform and our team in order to enhance our business model and position BlackRock to capture market opportunities - and most importantly, to partner with our clients to help them meet their investment goals." The full research reports on BlackRock are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/BLK/report.pdf

--
Allergan Inc. Research Reports
On October 27, 2014, Allergan Inc. (Allergan) announced its Q3 2014 earnings results. Product net sales were reported at $1.8 billion, up 17.2% YoY. Net earnings attributable to Allergan came in at $312.5 million or $1.03 per diluted share, versus $299.8 million or $1.00 per diluted share in Q3 2013. Allergan reported non-GAAP earnings of $1.78 per diluted share, compared to $1.23 in Q3 2013. David E.I. Pyott, Allergan's Chairman of the Board and CEO said, "With continuing strong momentum across a broad range of products, Allergan again recorded the strongest increase in absolute dollar sales in any quarter in our history, and again delivered sales and earnings per share growth above the high end of our expectations." For the full year 2014, Allergan expects total product net sales to range between $7,080 million and $7,155 million and non-GAAP diluted EPS within $6.27 and $6.30. The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/AGN/report.pdf

--
Cabot Oil & Gas Corporation Research Reports
On October 24, 2014, Cabot Oil & Gas Corporation (Cabot) announced its Q3 2014 financial and operating results. During the quarter, Cabot's production increased 24% YoY 132.4 billion cubic feet equivalent (Bcfe). Production at Marcellus Shale averaged 1,298 million cubic feet (Mmcf) per day, an increase of 30% YoY. Cabot's net production in the Eagle Ford during the quarter increased 37% YoY to 10,347 barrels of oil equivalent (Boe) per day. Operating Revenue was reported at $512.0 million, versus $435.9 million in Q3 2013. Net income arrived at $100.8 million, or $0.24 per share, compared to $69.9 million, or $0.17 per share, in Q3 2013. "The results posted in the most recently completed quarter once again highlight the quality of our operations and assets," said Dan O. Dinges, Chairman, President and CEO of Cabot. "We made improvements in every key category, even in the face of strong headwinds." The Company has reaffirmed its 2015 production growth guidance range of 20 to 30%. The full research reports on Cabot are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/COG/report.pdf

--
Cheniere Energy, Inc. Research Reports
On October 24, 2014, Cheniere Energy Partners, L.P. a subsidiary of Cheniere Energy, Inc. (Cheniere Energy) announced a cash distribution per common unit of $0.425 to unitholders of record as of November 3, 2014, and the related distribution to its general partner. According to the Company, the said distributions are payable on November 14, 2014. The full research reports on Cheniere Energy are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/LNG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED